drugset / Trial / NCT04425837
Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19
RandomizedParallel-groupSingle-blindTreatment
Summary
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected the global population with significant morbidity and mortality. One of the main concerns is the management of the patients since there is no specific treatment for this condition. Therefore, in SARS-CoV-2 patients the compassionate use of off-label therapies has been initiated; such as the use of plasma from convalescent patients. This treatment has been used in other pandemics like SARS-CoV-1, H5N1, H1N1, Ebola, among others. This study is a phase II/III randomized clinical trial to assess the effectiveness and safety of convalescent plasma administration in patients with high-risk SARS-CoV-2.
Timeline
- Start
- 2020-07
- Primary completion
- 2021-02
- Completion
- 2021-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-SARS-CoV-2 convalescent plasma | Protein / enzyme biologic | 400 ml | Intravenous |